MediWound (MDWD) news
Recent news
Mediwound - Total program budget for Nextrid development raised to $21.80 mln
MediWound Ltd. has announced an increase in the total program budget for the development of Nextrid, its lead product candidate, to $21.80 million. This adjustment reflects the company’s ongoing commitment to advancing the clinical development of the treatment, which is designed for the management…
AInvest Wire · Sep 22, 2026Mediwound - Interim assessment and enrollment completion on track for end of Q1 2027
MediWound Ltd. (MDWD) reported during its first-quarter 2026 earnings call that the interim sample size reassessment and enrollment completion for its Phase III VALUE study of EscharEx in venous leg ulcers remain on track for the end of the first quarter of 2027. CEO Ofer Gonen noted that while…
AInvest Wire · Sep 14, 2026Mediwound - DSBM did not identify safety concerns in pre-specified review
Mediwound (NASDAQ: MDWD) has received a favorable outcome from the Division of Biologics and Medical Devices (DSBM) regarding a pre-specified safety review of its product development program. The DSBM did not identify any safety concerns during its evaluation, according to the latest update from…
AInvest Wire · Sep 14, 2026MEDIWOUND FY 2026 revenue guidance reaffirmed at $24-26M
AInvest Wire · May 27, 2026MediWound: FDA accepted for review supplement to Nexobrid Bla.
MediWound: FDA accepted for review supplement to Nexobrid Bla. MediWound, a biotechnology company specializing in tissue repair and regeneration, has recently received positive news from the US Food and Drug Administration (FDA). The FDA has accepted MediWound's re-submitted Biologics License…
AInvest Wire · Jan 9, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.